Cell Specific CD44 Expression in Breast Cancer Requires the Interaction of AP-1 and NFκB with a Novel cis-Element

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Smith, Shannon M ^a   Cai, Li ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB;

ARTICLE; BINDING ASSAY; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; PROTEIN DNA BINDING; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIGENS, CD44; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CONSERVED SEQUENCE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NF-KAPPA B; ORGAN SPECIFICITY; PROTEIN BINDING; REGULATORY SEQUENCES, NUCLEIC ACID; SEQUENCE ALIGNMENT; TRANSCRIPTION FACTOR AP-1;

EID: 84870683675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050867     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
3. Fillmore C, Kuperwasser C, (2007) Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9: 303.
4. Fillmore CM, Kuperwasser C, (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
5. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE, (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174.
6. Dave B, Chang J, (2009) Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 14: 79-82.
7. Marotta LL, Polyak K, (2009) Cancer stem cells: a model in the making. Curr Opin Genet Dev 19: 44-50.
8. Foster LC, Wiesel P, Huggins GS, Panares R, Chin MT, et al. (2000) Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. FASEB J 14: 368-378.
9. Ponta H, Sherman L, Herrlich PA, (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45.
10. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, et al. (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59.
11. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV, (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18: 260-267.
12. Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, et al. (2000) CD44 expression and regulation during mammary gland development and function. J Cell Sci 113 (Pt 14): 2619-2630.
13. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, et al. (2000) CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 910: 106-118; discussion 118-120.
14. Orian-Rousseau V, (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271-1277.
15. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
16. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG, (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286: 11314-11327.
17. Ameyar M, Wisniewska M, Weitzman JB, (2003) A role for AP-1 in apoptosis: the case for and against. Biochimie 85: 747-752.
18. Eferl R, Wagner EF, (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
19. Mao X, Orchard G, Mitchell TJ, Oyama N, Russell-Jones R, et al. (2008) A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol 35: 899-910.
20. Damm S, Koefinger P, Stefan M, Wels C, Mehes G, et al. (2010) HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol 130: 1893-1903.
21. Heintzman ND, Ren B, (2009) Finding distal regulatory elements in the human genome. Curr Opin Genet Dev 19: 541-549.
22. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, et al. (2009) Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459: 108-112.
23. Orom UA, Shiekhattar R, (2011) Noncoding RNAs and enhancers: complications of a long-distance relationship. Trends in genetics: TIG 27: 433-439.
24. Wang J, Zhuang J, Iyer S, Lin X, Whitfield TW, et al. (2012) Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res 22: 1798-1812.
25. Vernot B, Stergachis AB, Maurano MT, Vierstra J, Neph S, et al. (2012) Personal and population genomics of human regulatory variation. Genome Res 22: 1689-1697.
26. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M, (2012) Linking disease associations with regulatory information in the human genome. Genome Res 22: 1748-1759.
27. Cheng C, Alexander R, Min R, Leng J, Yip KY, et al. (2012) Understanding transcriptional regulation by integrative analysis of transcription factor binding data. Genome Res 22: 1658-1667.
28. Arvey A, Agius P, Noble WS, Leslie C, (2012) Sequence and chromatin determinants of cell-type-specific transcription factor binding. Genome Res 22: 1723-1734.
29. Doh ST, Zhang Y, Temple MH, Cai L, (2007) Non-coding sequence retrieval system for comparative genomic analysis of gene regulatory elements. BMC Bioinformatics 8: 94.
30. Brudno M, Do CB, Cooper GM, Kim MF, Davydov E, et al. (2003) LAGAN and Multi-LAGAN: efficient tools for large-scale multiple alignment of genomic DNA. Genome Res 13: 721-731.
31. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
32. Nohr J, Kristiansen K, (2003) Site-directed mutagenesis. Methods Mol Biol 232: 127-131.
33. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, et al. (2006) Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66: 3541-3549.
34. Fullwood MJ, Han Y, Wei CL, Ruan X, Ruan Y (2010) Chromatin interaction analysis using paired-end tag sequencing. Curr Protoc Mol Biol Chapter 21: Unit 21 15 21-25.
35. Visel A, Minovitsky S, Dubchak I, Pennacchio LA, (2007) VISTA Enhancer Browser-a database of tissue-specific human enhancers. Nucleic Acids Res 35: D88-92.
36. Visel A, Prabhakar S, Akiyama JA, Shoukry M, Lewis KD, et al. (2008) Ultraconservation identifies a small subset of extremely constrained developmental enhancers. Nat Genet 40: 158-160.
37. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
38. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
39. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, et al. (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10.
40. Zoller M, (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11: 254-267.
41. Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D, (2008) DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther 7: 1615-1623.
42. Young MR, Colburn NH, (2006) Fra-1 a target for cancer prevention or intervention. Gene 379: 1-11.
43. Ramos-Nino ME, Blumen SR, Pass H, Mossman BT, (2007) Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. Mol Cancer 6: 81.
44. Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, et al. (1997) AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 17: 963-976.
45. Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, et al. (1993) A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53: 1516-1521.
46. Risse-Hackl G, Adamkiewicz J, Wimmel A, Schuermann M, (1998) Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene 16: 3057-3068.
47. Dupont VN, Gentien D, Oberkampf M, De Rycke Y, Blin N, (2007) A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 121: 1036-1046.